| Literature DB >> 26587339 |
Wael M El-Deeb1, Sébastien Buczinski2.
Abstract
The present study aimed to investigate the diagnostic and prognostic importance of oxidative stress biomarkers and acute phase proteins in urinary tract infection (UTI) in camels. We describe the clinical, bacteriological and biochemical findings in 89 camels. Blood and urine samples from diseased (n = 74) and control camels (n = 15) were submitted to laboratory investigations. The urine analysis revealed high number of RBCS and pus cells. The concentrations of serum and erythrocytic malondialdehyde (sMDA & eMDA), Haptoglobin (Hp), serum amyloid A (SAA), Ceruloplasmin (Cp), fibrinogen (Fb), albumin, globulin and interleukin 6 (IL-6) were higher in diseased camels when compared to healthy ones. Catalase, super oxide dismutase and glutathione levels were lower in diseased camels when compared with control group. Forty one of 74 camels with UTI were successfully treated. The levels of malondialdehyde, catalase, super oxide dismutase, glutathione, Hp, SAA, Fb, total protein, globulin and IL-6 were associated with the odds of treatment failure. The MDA showed a great sensitivity (Se) and specificity (Sp) in predicting treatment failure (Se 85%/Sp 100%) as well as the SAA (Se 92%/Sp 87%) and globulin levels (Se 85%/Sp 100%) when using the cutoffs that maximizes the sum of Se + Sp. Multivariate logistic regression analysis revealed that two models had a high accuracy to predict failure with the first model including sex, sMDA and Hp as covariates (area under the receiver operating characteristic curve (AUC) = 0.92) and a second model using sex, SAA and Hp (AUC = 0.89). Conclusively, the oxidative stress biomarkers and acute phase proteins could be used as diagnostic and prognostic biomarkers in camel UTI management. Efforts should be forced to investigate such biomarkers in other species with UTI.Entities:
Keywords: Camel; Infections; Malondialdehyde; Serum Amyloid A; Urinary
Year: 2015 PMID: 26587339 PMCID: PMC4647549 DOI: 10.7717/peerj.1363
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Descriptive results and univariate analysis of blood biomarkers in camels with clinical diagnosis of UTI and in healthy camels.
| Clinical cases ( | Healthy cases ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Mean | Median | Minimum | Maximum | Mean | Median | Minimum | Maximum | |
| Age (Year) | 7.11 | 7.00 | 5.40 | 10.20 | 6.03 | 5.90 | 3.80 | 7.80 | 0.009 |
| eMDA (nmol/g Hb) | 180.80 | 180.36 | 104.23 | 222.36 | 109.41 | 109.36 | 101.36 | 113.54 | <0.0001 |
| sMDA (nmol/g protein)) | 19.01 | 19.30 | 10.10 | 24.64 | 10.85 | 11.11 | 10.23 | 11.60 | <0.0001 |
| CAT | 11.36 | 10.33 | 8.56 | 20.10 | 15.67 | 15.60 | 15.20 | 16.30 | <0.0001 |
| GSH (mmol/g Hb) | 4.10 | 3.80 | 2.20 | 9.11 | 6.78 | 6.80 | 6.30 | 7.20 | <0.0001 |
| SOD (U/mg Hb) | 3.73 | 3.45 | 2.12 | 8.12 | 4.98 | 4.90 | 4.50 | 5.80 | <0.0001 |
| Cp (g/L) | 1.06 | 1.09 | 0.08 | 3.60 | 0.09 | 0.09 | 0.08 | 0.10 | <0.0001 |
| HP (g/L) | 2.45 | 2.34 | 0.10 | 6.50 | 0.31 | 0.31 | 0.26 | 0.35 | 0.0002 |
| SAA (µg/mL) | 15.70 | 13.77 | 8.85 | 28.60 | 9.50 | 9.60 | 8.90 | 9.90 | <0.0001 |
| Fibrinogen (g/L) | 4.28 | 4.20 | 2.40 | 7.60 | 3.27 | 3.30 | 2.80 | 3.60 | <0.0001 |
| Total protein (g/L) | 6.85 | 6.32 | 5.38 | 8.90 | 6.05 | 5.90 | 5.40 | 7.20 | 0.12 |
| Albumen (g/L) | 2.64 | 2.57 | 2.30 | 3.30 | 3.13 | 3.10 | 2.80 | 3.60 | <0.0001 |
| Globulin (g/L) | 4.21 | 3.45 | 2.50 | 6.42 | 2.91 | 2.90 | 2.40 | 3.80 | <0.0001 |
| BUN (mg/dl) | 11.52 | 11.23 | 9.69 | 16.32 | 11.16 | 11.30 | 9.60 | 12.80 | 0.64 |
| Créatinine (mg/dL) | 0.88 | 0.87 | 0.50 | 1.23 | 0.95 | 0.94 | 0.80 | 1.20 | 0.11 |
| IL-6 (pg/mL)) | 15.08 | 14.43 | 11.23 | 21.36 | 12.35 | 12.36 | 10.23 | 13.87 | 0.003 |
Notes.
Urinary Tract Infection
erythrocytic malondialdehyde
Serum malondialdehyde
super oxide dismutase
glutathione
catalase
Haptoglobin
Serum Amyloid A
Ceruloplasmin
blood urea nitrogen
Fibrinogen
interleukin 6
P-value resulting from non-parametric Wilcoxon Mann-Whitney test.
Description of the variables depending on the success or failure with the treatment.
| Success cases ( | Failure cases ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Mean | Median | Minimum | Maximum | Mean | Median | Minimum | Maximum | |
| Age (Year) | 6.72 | 6.80 | 5.50 | 8.40 | 7.43 | 7.20 | 5.40 | 10.20 | 0.01 |
| eMDA (nmol/g Hb) | 163.99 | 171.36 | 104.23 | 182.36 | 194.66 | 211.36 | 105.36 | 222.36 | <0.0001 |
| sMDA (nmol/g protein)) | 16.65 | 17.36 | 10.11 | 19.36 | 20.92 | 22.58 | 10.10 | 24.64 | <0.0001 |
| CAT (U/mg Hb) | 12.15 | 11.60 | 9.30 | 20.10 | 10.72 | 9.40 | 8.56 | 16.36 | |
| GSH (mmol/g Hb) | 4.83 | 4.20 | 3.60 | 9.11 | 3.51 | 3.10 | 2.20 | 7.32 | <0.0001 |
| SOD (U/mg Hb) | 4.25 | 3.80 | 3.10 | 8.12 | 3.32 | 3.10 | 2.12 | 7.25 | <0.0001 |
| Cp (g/L) | 1.23 | 0.93 | 0.08 | 3.60 | 0.93 | 1.09 | 0.08 | 3.50 | 0.15 |
| HP (g/L) | 3.30 | 3.60 | 0.10 | 6.50 | 1.78 | 1.30 | 0.23 | 5.20 | 0.005 |
| SAA (µg/mL) | 19.67 | 19.70 | 8.85 | 28.60 | 12.51 | 11.86 | 8.96 | 25.30 | <0.0001 |
| Fibrinogen (g/L) | 4.72 | 4.60 | 2.94 | 7.60 | 3.92 | 3.90 | 2.40 | 5.80 | 0.002 |
| Total protein (g/L) | 5.70 | 5.70 | 5.38 | 6.34 | 7.77 | 7.90 | 5.42 | 8.90 | <0.0001 |
| Albumen (g/L) | 2.62 | 2.56 | 2.30 | 3.20 | 2.65 | 2.58 | 2.38 | 3.30 | 0.3 |
| Globulin (g/L) | 3.08 | 3.12 | 2.50 | 3.72 | 5.12 | 5.24 | 2.97 | 6.42 | <0.0001 |
| BUN (mg/dL) | 10.89 | 10.80 | 9.78 | 12.40 | 12.02 | 11.54 | 9.69 | 16.32 | 0.003 |
| Creatinine (mg/dL) | 0.84 | 0.82 | 0.50 | 1.20 | 0.91 | 0.90 | 0.59 | 1.23 | 0.07 |
| IL-6 (pg/mL)) | 16.69 | 18.25 | 11.23 | 21.36 | 13.79 | 13.69 | 11.23 | 19.36 | 0.0004 |
Notes.
erythrocytic malondialdehyde
Serum malondialdehyde
super oxide dismutase
glutathione
catalase
Haptoglobin
Serum Amyloid A
Ceruloplasmin
blood urea nitrogen
Fibrinogen
interleukin 6
P-value resulting from non-parametric Wilcoxon Mann-Whitney test.
The optimized cutoff of all selected biomarkers and their respective sensitivity (Se) and specificity (Sp) to detect failure or success.
| Variables | Criterion observed | Se | Sp | Bootstrap CI | Criterion used | AUC | 95% CI | |
|---|---|---|---|---|---|---|---|---|
| eMDA (nmol/g Hb) | >182.36 | 0.850 | 1.0 | 180.34–182.36 | 180 | 0.867 | 0.767–0.935 | <0.0001 |
| sMDA (nmol/g protein)) | >19.36 | 0.854 | 1.0 | 18.4–19.36 | 19 | 0.866 | 0.767–0.934 | <0.0001 |
| CAT (U/mg Hb) | ≤9.4 | 0.512 | 0.909 | 9.1–10.69 | 9.4 | 0.72 | 0.603–0.818 | 0.002 |
| GSH (mmol/g Hb) | ≤3.6 | 0.781 | 0.909 | 3.3–3.6 | 3.5 | 0.854 | 0.753–0.925 | <0.0001 |
| SOD (U/mg Hb) | ⩽3.4 | 0.805 | 0.879 | 3.1–3.4 | 3 | 0.817 | 0.711–0.898 | <0.0001 |
| Cp (g/L) | ≤0.13 | 0.390 | 0.879 | 0.08–0.13 | NU | 0.600 | 0.479–0.712 | 0.15 |
| HP (g/L) | ≤3.39 | 0.902 | 0.606 | 1.34–3.39 | 3 | 0.698 | 0.581–0.800 | 0.005 |
| SAA (µg/mL) | ≤15.6 | 0.927 | 0.879 | 13.8–15.6 | 15 | 0.853 | 0.751–0.924 | <0.0001 |
| Fibrinogen (g/L) | ≤4.23 | 0.756 | 0.667 | 3.4–4.5 | 4 | 0.717 | 0.600–0.815 | 0.002 |
| Total protein (g/L) | >6.34 | 0.878 | 1.0 | 5.8–6.34 | 6.0 | 0.938 | 0.857–0.981 | <0.0001 |
| Albumen (g/L) | >2.53 | 0.732 | 0.455 | 2.36–2.79 | NU | 0.571 | 0.451–0.686 | 0.3 |
| Globulin (g/L) | >3.72 | 0.854 | 1.0 | 3.27–3.72 | 3.5 | 0.940 | 0.859–0.982 | <0.0001 |
| BUN (mg/dL) | >12.3 | 0.488 | 0.939 | 10.6–12.3 | 12 | 0.712 | 0.595–0.811 | 0.003 |
| Creatinine (mg/dL) | >0.95 | 0.488 | 0.758 | 0.68–1.06 | 0.95 | 0.626 | 0.506–0.736 | 0.07 |
| IL–6 (pg/mL) | ≤15.47 | 0.902 | 0.727 | 12.36–15.47 | 15 | 0.751 | 0.637–0.844 | 0.0004 |
Notes.
erythrocytic malondialdehyde
Serum malondialdehyde
super oxide dismutase
glutathione
catalase
Haptoglobin
Serum Amyloid A
Ceruloplasmin
blood urea nitrogen
Fibrinogen
interleukin 6
not used since univariate analysis was higher than 0.1 or because not interesting per se.
sensitivity of the threshold indicates the number of cases positive (with treatment failure) for the tests/total number of cases
specificity of the threshold indicates the number of cases with treatment success with a negative test/total number of treatment success
P-value resulting from non-parametric Wilcoxon Mann-Whitney test.
A internal resampling with replacement using bootstrap technique was used to derive the interval which contained 95% of the observed J based on these 1,000 datasets.
The cutoff chosen for further modeling was chosen within interval of distribution of J as a rounded value to be used in a dichotomous covariate in multivariate analysis.
AUC: area under the receiver operating characteristic curve. The AUC was derived from the non-parametric ROC curve obtained using the initial dataset.
95% confidence interval for the AUC.
The two logistic regression models predicting the probability of treatment failure in camels with cystitis.
| Model | Variable | Coefficient | SE | OR | 95% CI | Joint |
|---|---|---|---|---|---|---|
| Model 1 | Intercept | −0.940 | 0.0.513 | – | – | 0.067 |
| Female | Ref | Ref | Ref | Ref | 0.04 | |
| Male | −1.734 | 0.847 | 0.17 | 0.034–0.928 | ||
| Low sMDA | Ref | Ref | Ref | Ref | <0.0001 | |
| High sMDA | 4.341 | 0.868 | 76.76 | 14.00–420.98 | ||
| Model 2 | Intercept | −1.981 | 0.533 | – | – | 0.0002 |
| Low SAA | Ref | Ref | Ref | Ref | <0.0001 | |
| High SAA | 4.206 | 0.749 | 67.06 | 15.44–291.28 |
Notes.
Odds Ratio
The cutoff chosen was 19 nmol/g protein (as shown in Table 3).
The cutoff used was 15 µg/mL as shown in Table 3.
Figure 1The receiver operating characteristic curves (ROC) of 2 different models.
TPF: true positive fraction; FPF: false positive fraction. Model 1 was the model including sex and sMDA as covariates. Model 2 included SAA as predictor of treatment failure.There was no difference between the 2 AUC (Mann-Whitney U test, P = 0.54).